Mabion S.A. Logo

Mabion S.A.

Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.

MAB | WAR

Overview

Corporate Details

ISIN(s):
PLMBION00016 (+1 more)
LEI:
259400KG5JVQPPZL6X53
Country:
Poland
Address:
Konstantynów Łódzki GEN. MARIANA LANGIEWICZA 60, 95-050 Konstantynów Łódzki
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Mabion S.A. is a biopharmaceutical Contract Development and Manufacturing Organization (CDMO) providing end-to-end services to pharmaceutical and biotech companies globally. The company specializes in the development, analytics, and manufacturing of complex biologic drugs. Mabion leverages advanced statistical methodologies, such as Design of Experiments (DoE), to optimize bioprocesses, enhance product quality, and ensure regulatory compliance. This data-driven approach supports accelerated development timelines and efficient, robust manufacturing for its partners, demonstrated through its involvement in large-scale production projects for biologics and vaccine components.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-17 14:10
Regulatory News Service
Załącznik 2_Strategia ESG Mabion S.A.
Polish 11.7 MB
2025-11-17 14:10
Regulatory News Service
Załącznik 1_Strategia Mabion S.A.
Polish 1.4 MB
2025-11-17 14:10
Management Discussion and Analysis
Przyjęcie Strategii Spółki Mabion S.A. na lata 2025 - 2030 oraz ujawnienie opóź…
English 8.3 KB
2025-11-17 14:10
Management Discussion and Analysis
Przyjęcie Strategii Spółki Mabion S.A. na lata 2025 - 2030 oraz ujawnienie opóź…
Polish 8.8 KB
2025-10-24 20:35
Related Party Transaction
Zawarcie z Twiti Investments Ltd. umowy pożyczki - Content (EN)
English 2.5 KB
2025-10-24 20:35
Capital/Financing Update
Zawarcie z Twiti Investments Ltd. umowy pożyczki - Content (PL)
Polish 2.4 KB
2025-10-08 15:16
Audit Report / Information
Informacja dotycząca stanowiska Zarządu i opinii Rady Nadzorczej Mabion S.A. od…
Polish 264.8 KB
2025-10-08 15:16
Interim Report
Raport Biegłego Rewidenta
Polish 497.9 KB
2025-10-08 15:16
Interim Report
Oświadczenie Zarządu w sprawie rzetelności sporządzenia sprawozdania finansowego
Polish 228.5 KB
2025-10-08 15:16
Management Discussion and Analysis
Mabion_Sprawozdanie Zarządu_1H2025
Polish 3.2 MB
2025-10-08 15:16
Interim Report
Mabion MSSF_1H2025
Polish 3.4 MB
2025-10-08 15:16
Audit Report / Information
Stanowisko Zarządu i opinia Rady Nadzorczej Mabion S.A. odnoszące się do odmowy…
Polish 368.1 KB
2025-10-08 14:27
Audit Report / Information
Stanowisko Zarządu i opinia Rady Nadzorczej Mabion S.A. odnoszące się do odmowy…
Polish 368.1 KB
2025-10-08 14:27
Audit Report / Information
Uzupełnienie raportu okresowego Spółki za I półrocze 2025 roku - Content (EN)
English 1.0 KB
2025-10-08 14:27
Report Publication Announcement
Uzupełnienie raportu okresowego Spółki za I półrocze 2025 roku - Content (PL)
Polish 784 bytes

Automate Your Workflow. Get a real-time feed of all Mabion S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Mabion S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Mabion S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

MiNK Therapeutics, Inc. Logo
Developing allogeneic iNKT cell therapies for cancer and immune-mediated diseases.
United States of America
INKT
MIRA PHARMACEUTICALS, INC. Logo
Develops novel ketamine and THC analogs for neurologic and neuropsychiatric disorders.
United States of America
MIRA
Mirum Pharmaceuticals, Inc. Logo
Develops and commercializes therapies for rare, debilitating liver diseases in children and adults.
United States of America
MIRM
Mithra Pharmaceuticals S.A. Logo
Biotech firm developing pharma for women's health: contraception, fertility, and menopause.
Belgium
MITRA
MIZUHO MEDY CO.,LTD. Logo
Develops rapid diagnostic tests & gene analyzers for clinical, research & agricultural markets.
Japan
4595
MOA Life Plus Co. Ltd. Logo
Develops immunotherapies & consumer solutions for immunity, skin rejuvenation, and pet care.
South Korea
142760
Moberg Pharma Logo
Develops & commercializes a leading topical treatment for nail fungus for European markets.
Sweden
MOB
Mochida Pharmaceutical Co.,Ltd. Logo
An R&D-driven company making drugs, skincare, and medical equipment for specialized fields.
Japan
4534
Moderna, Inc. Logo
Pioneering mRNA science to create transformative medicines and vaccines for diverse diseases.
United States of America
MRNA
Monopar Therapeutics Logo
Clinical-stage biotech developing radiopharmaceuticals for oncology and therapies for rare diseases.
United States of America
MNPR

Talk to a Data Expert

Have a question? We'll get back to you promptly.